AOD-9604 5mg

AOD-9604 5mg Research Peptide UK

AOD-9604 5mg is a synthetic 16-amino acid hexadecapeptide with molecular formula C78H123N23O23S2 and a molecular weight of approximately 1,817 Da. It is derived from the C-terminal region of human growth hormone, specifically amino acids 176 to 191, with an additional tyrosine residue at the N-terminus. This N-terminal tyrosine modification — making it technically Tyr-hGH Fragment 177-191 — distinguishes the aod 9604 5mg research peptide from unmodified HGH Fragment 176-191 and contributes to its stability profile in laboratory conditions.

The defining research property of AOD-9604 is its IGF-1 independence. Unlike full-length hGH, AOD-9604 5mg does not bind the growth hormone receptor (GHR) and does not stimulate IGF-1 production. This eliminates IGF-1 elevation as a confounding variable in metabolic study designs — a critical advantage when the objective is to investigate lipolytic pathway activity in isolation from the anabolic, mitogenic, and glucose-modulating effects associated with full-length hGH.

The primary mechanism of AOD-9604 in laboratory research models is selective beta-3 adrenergic receptor (beta-3 AR) activation. This triggers the cAMP signalling cascade, which activates protein kinase A (PKA), leading to hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) activation, resulting in triglyceride hydrolysis in adipocyte cell models. Published preclinical literature also documents aod 9604 peptide research in lipogenesis inhibition — suppression of new triglyceride formation — providing a dual-action metabolic profile distinct from compounds affecting only one arm of fat metabolism.

The 5mg format of aod 9604 research is appropriate for pilot investigations, method validation, dose selection studies, and first-time AOD-9604 research. For established programmes requiring full dose-response concentration gradients across multiple arms, AOD-9604 10mg provides the advanced format. For complementary metabolic pathway research through the IGF-1 receptor axis rather than beta-3 AR, IGF-1 LR3 1mg provides a mechanistically non-overlapping research tool.

Full mechanism, beta-3 AR pathway detail, and research design guidance are available in the AOD-9604 5mg research guide on the Ascend Peptides UK blog.

All batches tested by Janoshik. HPLC greater than or equal to 98%. LC-MS confirms N-terminal Tyr intact.

For laboratory handling purposes, AOD-9604 may be reconstituted using bacteriostatic water or other suitable aqueous solvents, depending on experimental design requirements. Store at -20°C under appropriate laboratory conditions.

WADA Status: Listed on WADA Prohibited List.

DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.